AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 9th, 2023 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • Connecticut
This Amended & Restated Executive Agreement (the “Agreement”) is made and entered into effective as of July 1, 2022 (the “Effective Date”), by and between Vincent O’Neill, M.D. (the “Executive”) and BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”).
FIRST AMENDMENT TO REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • May 9th, 2023 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Revenue Interest Financing Agreement (this “Amendment”) is made as of August 4, 2022, by and among BIOXCEL THERAPEUTICS, INC., a Delaware corporation (the “Company”), the purchasers party hereto (collectively, the “Purchasers” and individually, a “Purchaser”) and OAKTREE FUND ADMINISTRATION, LLC, as administrative agent on behalf of the Purchasers (in such capacity, together with its successors and assigns, the “Administrative Agent”).
RESTRICTED STOCK UNIT AWARD AGREEMENT GRANT NOTICERestricted Stock Unit Award Agreement • May 9th, 2023 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations
Unless otherwise defined herein, the terms defined in the OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC Management Incentive Plan (the “Plan”) shall have the same defined meanings in this Restricted Stock Unit Award Agreement, which includes the terms in this Grant Notice (the “Grant Notice”) and Appendix A attached hereto (collectively, the “Agreement”).
